Herein we report the combination of adalimumab and ustekinumab to successfully treat a 39-year-old woman who presented for evaluation of hidradenitis suppurativa in the setting of Crohn disease of both the small and large intestine. The patient reported previous control of her hidradenitis when she was using adalimumab for her Crohn disease. She had recently been started on ustekinumab for Crohn disease and had flaring of her hidradenitis. The patient re-started on adalimumab weekly and ustekinumab every 8 weeks. After one month, the patient reported clear improvement in her hidradenitis and Crohn disease with the combined therapy
: To date, adalimumab (ADA) is the only biotechnology drug approved for the management of hidradenit...
BACKGROUND: There is clear benefit from combination therapy with infliximab and immunosuppressive dr...
The introduction of tumor necrosis factor (TNF) inhibitors has significantly changed the treatment l...
A sporadic association between hidradenitis suppurativa and other diseases is reported in the litera...
Hidradenitis suppurativa (HS) is a chronic, inflammatory disease characterized by recurring abscesse...
We present a case of refractory ileocolonic Crohn’s disease in a 27-year-old female treated with dua...
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease characterized by recurring abs...
<p><strong>Aim:</strong> To discuss the new beneficial effect of adalimumab in the management of hid...
Abstract Guselkumab appears to be safe and effective in the treatment of patients with HS, who do no...
Hidradenitis suppurativa is a chronic disease that affects the apocrine gland-bearing regions of the...
Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a re...
The introduction of TNF blockers in the therapeutic armamentarium of inflammatory bowel diseases (IB...
Anti-tumour necrosis factor-alpha has dramatically changed the natural history of Crohn's disease in...
Hidradenitis suppurativa (HS) is a chronic, burdensome inflammatory skin disorder mainly affecting a...
Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective treatment for pati...
: To date, adalimumab (ADA) is the only biotechnology drug approved for the management of hidradenit...
BACKGROUND: There is clear benefit from combination therapy with infliximab and immunosuppressive dr...
The introduction of tumor necrosis factor (TNF) inhibitors has significantly changed the treatment l...
A sporadic association between hidradenitis suppurativa and other diseases is reported in the litera...
Hidradenitis suppurativa (HS) is a chronic, inflammatory disease characterized by recurring abscesse...
We present a case of refractory ileocolonic Crohn’s disease in a 27-year-old female treated with dua...
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease characterized by recurring abs...
<p><strong>Aim:</strong> To discuss the new beneficial effect of adalimumab in the management of hid...
Abstract Guselkumab appears to be safe and effective in the treatment of patients with HS, who do no...
Hidradenitis suppurativa is a chronic disease that affects the apocrine gland-bearing regions of the...
Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a re...
The introduction of TNF blockers in the therapeutic armamentarium of inflammatory bowel diseases (IB...
Anti-tumour necrosis factor-alpha has dramatically changed the natural history of Crohn's disease in...
Hidradenitis suppurativa (HS) is a chronic, burdensome inflammatory skin disorder mainly affecting a...
Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective treatment for pati...
: To date, adalimumab (ADA) is the only biotechnology drug approved for the management of hidradenit...
BACKGROUND: There is clear benefit from combination therapy with infliximab and immunosuppressive dr...
The introduction of tumor necrosis factor (TNF) inhibitors has significantly changed the treatment l...